Startups
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.
Overview
Location
United States, Indiana, York
Employees
1001-5000
Founded date
1971
Mentions in press and media 14
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 11, 2026 | Peptide Synthesis Market Trends: Drug Development and Biopharmaceutical Innovation Driving Growth | The peptide synthesis market is witnessing strong growth as peptides gain increasing importance in pharmaceutical research, therapeutic development, diagnostics, and biotechnology. Peptide synthesis enables the production of customized pept... |
| Jul 20, 2026 | Samsung Biologics Buys PolyPeptide in $1.81 Billion Deal to Enter GLP-1 Drug Manufacturing | By Henry Baker Published: Jul 20 2026, 3:57 PM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| Nov 18, 2025 | TIRmed Enters into Collaboration with Bachem to Advance Oligonucleotide Therapy for Atopic Dermatitis | TIRmed Enters into Collaboration with Bachem to Advance Oligonucleotide Therapy for Atopic Dermatitis Tue, Nov 18, 2025 07:00 CET Report this content TIRmed Pharma, a biotechnology company developing next-generation treatments for autoimmun... |
| Sep 9, 2024 | Managing Compliance Risk in Life Sciences: How Can IT and Quality Teams Root it Out | www.sware.com In this free webinar, learn how information technology (IT) and quality teams in life sciences organizations can both protect and deliver exceptional value by developing a systematic way to assess and grade risk, strengthening... |
| Oct 19, 2021 | Bachem : raises CHF 583.5 million through capital increase | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLA... |
| Oct 18, 2021 | Bachem : launches accelerated bookbuilding for approx. 750k new shares | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLA... |
| Aug 19, 2021 | Bachem : Propofol – A Bachem success story | The COVID-19 pandemic has rapidly expanded awareness of the API propofol, produced by Bachem in Vionnaz. We are both pleased by, and proud of, Bachem's prompt response to sharply higher demand. Based on a prudent business continuity managem... |
| Jul 20, 2021 | Bachem : What are oligonucleotides? | Our genetic information is stored in repeating sequence of nucleotides, abbreviated by the letters A, C, G, T in DNA, and A, C, G, U in RNA. DNA is a very large molecule that contains millions of nucleotides! Oligonucleotides are short sing... |
| Jul 1, 2021 | Bachem : What are somatostatin and somatostatin analogues? | Somatostatin (SST) was isolated and characterized by researchers working in the laboratory of Guillemin at the Salk Institute in 19731Burgus, R et al. Proc. Natl. Acad. Sci. U. S. A. 70(3), 684-688 (1973). Somatostatin is a hormone produced... |
Show more
Reviews 0
FAQ about Bachem
When was Bachem founded?
Bachem was founded in 1971.
What has the press written about Bachem?
Parsers VC has collected 14 articles mentioning Bachem, among them “Peptide Synthesis Market Trends: Drug Development and Biopharmaceutical Innovation Driving Growth” (Aug 11, 2026) and “Samsung Biologics Buys PolyPeptide in $1.81 Billion Deal to Enter GLP-1 Drug Manufacturing” (Jul 20, 2026).
Is Bachem still active?
Yes, Bachem is active; its latest activity on Parsers VC dates from Oct 9, 2026.